Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reiterated by research analysts at Numis Securities Ltd in a report issued on Monday. They currently have a GBX 37 ($0.48) price target on the stock. Numis Securities Ltd’s price target suggests a potential upside of 89.74% from the stock’s current price.

A number of other brokerages also recently commented on AGY. Panmure Gordon reissued a “buy” rating and issued a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a report on Thursday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.

Shares of Allergy Therapeutics plc (LON:AGY) opened at 21.70 on Monday. The stock’s market capitalization is GBX 127.85 million. The company has a 50 day moving average price of GBX 18.82 and a 200-day moving average price of GBX 22.15. Allergy Therapeutics plc has a 1-year low of GBX 17.25 and a 1-year high of GBX 34.82.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other news, insider Nicolas Wykeman bought 150,000 shares of Allergy Therapeutics plc stock in a transaction on Tuesday, September 27th. The shares were bought at an average price of GBX 18 ($0.23) per share, with a total value of £27,000 ($35,243.44). Also, insider Peter Jensen bought 30,000 shares of Allergy Therapeutics plc stock in a transaction on Thursday, September 29th. The shares were purchased at an average cost of GBX 19 ($0.25) per share, for a total transaction of £5,700 ($7,440.28).

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with's FREE daily email newsletter.